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Purpose: To evaluate the effect of adherence to evidence-based guidelines of the Surviving Sepsis
Campaign (SSC) on the outcome of cirrhotic patients with septic shock admitted to the intensive care unit.
Methods: This prospective observational cohort study included 38 patients with documented liver
cirrhosis and septic shock admitted to a multidisciplinary intensive care unit at a University Hospital from
January 2005 to June 2009. In each patient, the compliance to 4 resuscitation (ie, 6-hour bundle) and to 3
management (i.e. 24-hour bundle) interventions recommended by the SSC guidelines and the 30-day
mortality were measured.
Results: The 6-hour, 24-hour, and all bundles were completed in 50 %, 52%, and 39% of the
patients, respectively. The characteristics at admission and the 30-day mortality of patients with all-
bundle compliance (n = 15; mortality 86.6%) were similar to those of patients without bundle
compliance (n = 23; mortality 78.2%), except for central venous O2 saturation. Unadjusted and
adjusted regression analysis showed that none of the single sepsis interventions and bundles were
independently associated with 30-day mortality.
Conclusions: In our observational study, the adherence to the interventions recommended by the SSC
evidence-based guidelines did not provide an improvement in the survival rate of cirrhotic patients
with septic shock.
© 2013 Elsevier Inc. All rights reserved.Abbreviations: SSC, Surviving Sepsis Campaign; ICU, intensive care unit; PaO2/FiO2, arterial O2 partial pressure to inspired O2 fraction
tio; MAP, mean arterial pressure; ALI, acute lung injury; ARDS, Adult respiratory distress syndrome; ScvO2, central venous oxygen
aturation; SAPS, Simpliﬁed Acute Physiology Score; SOFA, simpliﬁed organ failure assessment; MELD, Model End-stage Liver Disease
core.
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153Effectiveness of sepsis bundle application1. Introduction
Liver cirrhosis is one of the most frequent chronic disease
over the world. In 2002, more than 300,000 adult men in the
European Union have died from liver cirrhosis complications
such as hemorrhage and sepsis [1]. End-stage liver disease is
a well-deﬁned risk factor for development of infections and
sepsis in cirrhotic patients is frequently associated with
encephalopathy, renal failure, and gastrointestinal bleeding
[2-4]. The mortality rate of cirrhotic patients with sepsis
greatly exceeds that of septic patients without liver disease,
approaching to 100% in patients requiring intensive care unit
(ICU) admission with 3 or more organ dysfunctions [5,6].
In 2004 and in 2008, the guidelines of the Surviving
Sepsis Campaign (SSC) [7,8] recommended a series of
evidence-based interventions (ie, sepsis bundles) whose
application ought to improve the outcome of patients with
severe sepsis and septic shock. Numerous recently pub-
lished articles showed that the application of the SSC was
effective in decreasing the hospital mortality of septic shock
patients [9,10], and this was the case also in our experience
[11]. However, the effectiveness of these interventions has
never been assessed in population with speciﬁc comorbid-
ities that can interfere with the normal inﬂammatory
responses to infection, as for instance, liver cirrhosis. In
this study we evaluated the effects of the sepsis in-
terventions proposed by SSC guidelines on the all-cause
30-day mortality in cirrhotic patients with septic shock
admitted to the intensive care unit (ICU).2. Methods
2.1. Patients
This prospective observational study enrolled patients
with liver cirrhosis and septic shock admitted from January
2005 to June 2009 to ICU of a University Hospital with a
liver transplantation program. The study was approved by
the local ethical committee. Most patients (90%) were in
waiting list for liver transplantation and had histological
documentation and/or a clear medical history of chronic
liver failure. The patient was considered to be in septic shock
if all the following conditions were satisﬁed: (i) mean
arterial pressure was less than 60 mmHg despite adequate
ﬂuid resuscitation, (ii) there were signs of tissue hypoperfu-
sion (eg, oliguria, acidosis, worsening of mental status), (iii)
there was evidence of systemic inﬂammatory response
syndrome (eg, body temperature N38°C or b36°C; tachy-
cardia, tachypnea, leukocytosis, or leukopenia), and (iv)
there was a microbiologically documented infection.
Patients with shock of uncertain etiology and with do not
resuscitate order or end-life decisions were not included in
the study. Only the ﬁrst episode of septic shock was
considered for each patient.2.2. Data collection
In each patient, the compliance to 4 resuscitation in-
terventions (6-hour bundle) and 3 management interventions
(24-hour bundle) was evaluated. The 6-hour bundle includes
(1) blood cultures collection before antibiotic administration
and (2) empiric antibiotic therapy within 3 hours from
diagnosis, adequate ﬂuid resuscitation before vasopressor
administration, and central venous oxygen saturation (ScvO2)
optimization within 6 hours (ScvO2 N70 %). The 24-hour
bundles includes: (1) blood glucose median b150mg/dL in the
ﬁrst 24 hours, (2) low-dose hydrocortisone administration in
association with vasopressor support, (3) plateau inspiratory
pressure b30 cm H2O in patients with acute lung injury/adult
respiratory distress syndrome. The term adequate ﬂuid
resuscitation indicates a central venous pressure N6 mm Hg
(N8mmHg ifmechanically ventilated) or a global end-diastolic
volume by trans-pulmonary thermodilution (PiCCO system,
Pulsion, Germany) N700 mL/m2. The use of recombinant
human activated protein C was not considered because of its
contraindications in patients with chronic liver disease.
Two of the authors (L.R. and L.D), not involved in the
management of the patients, collected the above interventions
by analysis of clinical charts, and any uncertain data were
reviewed with the attending physician. The interventions
were classiﬁed in a dichotomous way, that is, completed or
not completed. If an intervention was not applied because it
not applicable (eg, low inspiratory pressure in patient without
acute lung injury/adult respiratory distress syndrome), it was
deﬁned as completed. The time zero for bundles timing was
the time in which signs of septic shock were documented by
clinical notes. Grade of sepsis, primary site of infection,
SAPS II and SOFA scores [12,13], and 30-day mortality were
also recorded for each patient. The grade of liver failure was
assessed at ICU admission using the Model End-Stage Liver
Disease (MELD) score [14].
2.3. Statistical analysis
χ2 Test and ANOVA single-factor analysis were used
when appropriate. Kaplan-Meier curves and log-rank tests
were used for the comparison of 30-day survival curves
between patients with and without sepsis bundles comple-
tion. To estimate the independent effect of each single
intervention and bundle on 30-day mortality, univariate
unadjusted and multivariate logistic regression adjusted for
age, MELD, and SOFA scores were used. Data analyses
were performed by means of SPSS version 15.0 (SPSS,
Chicago, IL) and P b .05 was considered signiﬁcant.3. Results
Thirty-eight patients with liver cirrhosis and septic shock
were studied (Table 1). Apart from steroids administration
Table 1 Main characteristics and laboratory data at ICU
admission in all the study population and in patients with and
without all-bundle completion
All
patients
Bundles
completed
Bundles not
completed
Patients (n) 38 15 23
Age (years; mean ± SD) 51 ± 10 50 ± 12 52 ± 10
Female (%) 29 27 30
Cirrhosis etiology
Viral, n (%) 28 (74) 12 (80) 16 (70)
Alcoholic, n (%) 6 (16) 1(7) 5 (22)
Other, n (%) 4 (10) 2 (13) 2 (9)
MELD score (mean ± SD) 35 ± 12 39 ± 11 33 ± 12
Site of infection
Pneumonia, n (%) 25 (66) 11 (73) 14 (61)
Intra-abdominal infection,
n (%)
15 (39) 6 (43) 9 (39)
Blood, n (%) 21 (55) 7 (47) 14 (61)
Urinary tract, n (%) 16 (42) 7 (47) 9 (39)
SAPS II (mean ± SD) 67 ± 20 68 ± 16 67 ± 22
SOFA (mean ± SD) 16 ± 3 17 ± 2 16 ± 3
Prothrombin time
(INR, mean ± SD)
3.1 ± 1.4 3.1 ± 1.4 3.1 ± 1.4
Bilirubin (mg/dL,
mean ± SD)
20 ± 15 25 ± 14 17 ± 15
Creatinine (mg/dL,
mean ± SD)
2.9 ± 2 3.7 ± 2.2 2.5 ± 1.8
RRT (n, %) 9 (24) 4 (27) 5 (22)
Lactate (mg/dL,
mean ± SD)
60 ± 47 61 ± 35 60 ± 54
ScvO2 (%) 78 ± 11 84 ± 7 ⁎ 76 ± 12
30 day mortality,
n (%)
31
(81.6)
13 (86.6) 18 (78.2)
Hospital mortality,
n (%)
32
(84.2)
13 (86.6) 19 (82.6)
⁎ P b .05 bundles completed vs. not completed.
154 L. Rinaldi et al.(58%), all the single interventions were completed in more
than 75% of the patients; the compliance to interventions
slightly increased during the study period and the 6-hoursFig. 1 Percentage of patients with compliance to each single interventio
details, see text.and 24-hours bundles were completed in 50 % and 52 % of
the patients, respectively (Fig. 1). The median time from
shock presentation to administration of broad spectrum
antibiotic was 58 min (interquartile range, 46-115 min ).
Before shock appearance, 24 patients (63%) were in
antibiotic therapy that was modiﬁed in 20 of these patients
after shock occurrence. Patients with compliance to all
bundles (39%) were quite similar to patients without
compliance, except ScvO2 that was higher (P b .05) in the
compliance group. Indeed, in this group, MELD score,
bilirubin, creatinine, and 30-day mortality were also larger
than in no-compliance group, but not so signiﬁcantly
(Table 1). The 7 patients survived at 30 days had better
severity scores and laboratory data at ICU admission than
those observed in no survivors, whereas the compliance to 6-
hour and 24-hour bundles was similar (Tables 2 and 3).
Kaplan-Maier plots indicated that the probability of remain-
ing alive was similar in patients with and without bundles
compliance (Fig. 2). The univariate unadjusted (Table 3) and
the multivariate logistic regression analysis adjusted for
MELD and SOFA scores showed that the compliance to the
single treatment included in the bundles nor the compliance
to 6-hour, 24-hour, and all bundles together were indepen-
dently associated with 30-days mortality.4. Discussion
This observational study indicated that the 30-day
mortality of cirrhotic patients with septic shock admitted to
ICU is extremely high and that the application of the
interventions recommended by SSC guidelines does not
seem to improve the survival rate in this population.
Due to their immunocompromised condition, cirrhotic
patients have a high risk of developing infections [3,4].
Sepsis occurs in approximately 40% of cirrhotic hospitalized
patients with an associated mortality rate signiﬁcantly larger
than in no-cirrhotic patients [5,6,14]. The evidence based
treatments proposed in the SSC guidelines and then and to 6 hours, 24 hours, and all the bundles. For abbreviations and
Table 2 Main characteristics and laboratory data at ICU
admission in survivors and no survivors at 30 days
Survivors No survivors
Patients (n) 7 31
Age (years; mean ± SD) 53±13 51±10
Female (%) 29 29
Cirrhosis etiology
Viral, n (%) 4 (57) 21 (68)
Alcoholic, n (%) 1 (14) 5 (16)
Other, n (%) 2 (28) 5 (16)
MELD score (mean ± SD) 22 ± 9 38 ± 10 ⁎
Site of infection
Pneumonia, n (%) 5 (71) 20 (64)
Intra-abdominal infection, n (%) 2 (28) 13 (42)
Blood (n, %) 4 (57) 17 (55)
Urinary tract (n, %) 2 (28) 14 (45)
SAPS II (mean ± SD) 47±13 71 ± 19 ⁎
SOFA (mean ± SD) 12 ± 4 16 ± 3 ⁎
Prothrombin Time (INR, mean ± SD) 1,8 ± 0,4 3,5 ± 1,3 ⁎
Bilirubin (mg/dL, mean ± SD) 14 ± 16 21 ± 14
Creatinine (mg/dL, mean ± SD) 1,0 ± 0,42 3,5 ± 2,0 ⁎
RRT (n, %) 0 (0) 9 (29)
Lactate (mg/dL, mean ± SD) 19 ± 12 72 ± 47 ⁎
ScvO2 (%) 82 ± 7 77 ± 12
RRT, renal replacement therapy before ICU admission.
⁎ P b .05 compared to survivors.
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in improving the survival rate of patients with severe sepsis
[7-11]. Indeed, the effects of these treatments in patients with
end-stage liver disease have never been assessed, except for
low dose steroids. Fernadez et al [15] demonstrated that
adrenal insufﬁciency is common in cirrhotic patients with
severe sepsis and that the administration of hydrocortisone
was associated with high frequency of shock resolution and
high survival rate. In our study hydrocortisone was
administered in around 60% of the patients but its use didTable 3 Odds ratio obtained by unadjusted univariate logistic regressi
24-hour bundles
Survivors (n = 7),
completed, n (%)
No
com
Single treatment
Blood culture 6 (86) 28
Antibiotic b3 h 4 (57) 26
Fluid resuscitation 5 (71) 28
ScvO2 optimization 5 (71) 26
Glycemia control 6 (86) 26
Steroids 4 (57) 19
Plateau pressure control 6 (86) 27
Bundles
6 h 2 (28) 18
24 h 3 (42) 17
All bundles 2 (28) 13
95% CI, 95% conﬁdence interval.not modify the survival rate. This discrepancy can be
justiﬁed, at least in part, by differences in the studied
populations: the MELD score of our patients calculated on
ICU admission (36 ± 12) exceeds the values observed by
Fernandez et al (ranging between 13 and 28) [15]. Moreover,
a recent randomized control trial indicated that in patients
with cirrhosis and septic shock the hydrocortisone therapy
was associated with hemodynamic improvement but did not
reduce mortality and was associated with an increase in
shock relapse and gastrointestinal bleeding [16].
In our patients, the 30-day mortality rate remained
extremely high and did not depend on application of sepsis
bundles. These negative results could be explained, in our
opinion, by the following reasons. First, we hypothesize, in
accordance with others [17], that some of the resuscitation
and management interventions proposed by the SSC
guidelines could be inadequate in cirrhotic patients. For
instance, it is well known that the central venous SO2 in
patients with end-stage liver disease is higher than normal
because of the vasodilated hyperdynamic state. Therefore,
the ScvO2 cut off value of 70% proposed by SSC guidelines
could be inappropriate in this context. Likewise, the use of
central venous pressure (CVP) value alone as target for ﬂuid
resuscitation could be misleading. In fact, the typical
hypoalbuminemic and vasodilated state of cirrhotic patients
can require a very large ﬂuid infusion before achieving the
suggested CVP values with an increased risk of interstitial
and pulmonary edema. Moreover, a rapid increase of CVP
values in cirrhotic patients can cause an additional risk in
relation to the increase of portal pressure with bleeding
complications and large ascites formation [17]. For the above
reasons, in our protocols for the management of cirrhotic
patients with sepsis, we decided to lower the CVP threshold
before vasoactive amine administration to 6 mmHg with
respect to 8 mmHg proposed by the SSC guidelines [7,8].
Second, the identiﬁcation of severe sepsis in a cirrhotic
patient may be very challenging as many of the clinical signson for 30-day mortality for each treatment completed in the 6- and
survivors (n = 31),
pleted, n (%)
OR (95% CI) P
(90) 1.11 (0.98-1.25) .38
(83) 3.90 (0.66-22.05) .12
(90) 3.73 (0.49-18.32) .18
(83) 2.80 (0.31-13.88) .44
(83) 0.87 (0.11-8.08) .88
(61) 1.19 (0.22-6.19) .52
(87) 1.56 (0.13-11.60) .72
(51) 8.31 (0.89-27.50) .07
(54) 1.62 (0.31-8.48) .57
(42) 4.33 (0.46-20.46) .17
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Fig. 2 Probability of survival in patients with (solid line) and
without (dotted line) compliance to all interventions (upper panel),
6-hour resuscitative bundle (middle panel), and 24-hour manage-
ment bundle (lower panel).
156 L. Rinaldi et al.of Systemic Inﬂammatory Response Syndrome and organ
dysfunction can be present also in a cirrhotic patients without
infection. For instance, hepatopulmonary and hepatorenal
syndromes often complicate the clinical course of cirrhotic
patients, leading to the development of severe respiratory and
renal dysfunctions [17]. To avoid possibility of uncertain
diagnosis, we included only cirrhotic patients with shock
who had a microbiologically documented infection. The time
of shock presentation was considered the time zero for
evaluating the application of sepsis bundles. This could have
caused a time delay between the application of the
recommended sepsis interventions and the onset of severe
sepsis. Therefore, it remains uncertain if an earlier
application (ie, before shock) of sepsis bundles would be
beneﬁcial in these patients.
At ICU admission, the extent of organ dysfunctions in
patients who survived were less severe than in dead patients:
plasmatic creatinine was within normal range while lactate
blood concentration and prothrombin time were only slightly
altered (Table 2). The high discriminative power of renal
function and SOFA score as independent variables in
predicting hospital mortality of critically ill cirrhotic patients
has been recently demonstrated [5]; as well, the strong
correlation between lactate blood concentration, organ
dysfunction and mortality in septic shock patients is well
known. These observations support the hypothesis that a
delay may have occurred in some patients before ICU
admission and the initiation of speciﬁc sepsis therapies.
Lastly, the low number of patients included, the high
compliance to sepsis interventions (ie, N75%), and the
design of the study (ie, observational) led to unavoidable
limitation, particularly in case of patients subgrouping and
model analysis. In fact, at ICU admission, the patients with
bundle compliance had clinical picture more severe (see
Table 1) than patients without compliance. This difference
further hinders deﬁnitive conclusions on the effectiveness of
SSC guidelines in our patients.
In conclusion, the cirrhotic patient with septic shock is a
challenge in the ICU because of its high clinical complexity
and its high mortality rate. In our small cohort of cirrhotic
patients with septic shock, the full application of interven-
tions recommended by the SSC did not modify the 30-day
mortality. We believe that the time of application and the
targets of the recommended interventions as well as new
speciﬁc therapeutic options (eg, artiﬁcial liver support)
should be the objective of future clinical trials in patients
with end-stage liver disease and septic shock.References
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